Investors

Press Releases

Press Releases

Date Title View
Toggle Summary Liquidia Initiates Phase 3 Clinical Trial of LIQ861 in Patients with Pulmonary Arterial Hypertension View HTML
Toggle Summary Liquidia Presents Positive LIQ861 Results at the Annual World Congress of the Pulmonary Vascular Research Institute View HTML
Toggle Summary Liquidia Technologies Added to Russell 2000®, 3000® and Microcap® Indexes
RESEARCH TRIANGLE PARK, N.C. , Sept. 24, 2018 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”) , a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT® technology to transform the
View HTML
Toggle Summary Liquidia Technologies Announces Closing of Initial Public Offering
RESEARCH TRIANGLE PARK, N.C. --(BUSINESS WIRE)--Jul. 30, 2018-- Liquidia Technologies, Inc. (the “Company”) , a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT® technology to transform the lives of
View HTML
Toggle Summary Liquidia Technologies Announces Positive Phase 1 Data for LIQ865, Sustained-Delivery PRINT® Formulation of Bupivacaine for Post-Surgical Pain Relief View HTML
Toggle Summary Liquidia Technologies Announces Pricing of Initial Public Offering
RESEARCH TRIANGLE PARK, N.C. --(BUSINESS WIRE)--Jul. 25, 2018-- Liquidia Technologies, Inc. (the “Company”) , a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT ® technology to transform the lives of
View HTML
Toggle Summary Liquidia Technologies Appoints Jeri Thomas as Senior Vice President, Commercial
Liquidia Technologies, Inc.  (“Liquidia”), a late-stage clinical biopharmaceutical company focused on improving the performance of medicine by precisely engineering drug particles, today announced the appointment of Jeri Thomas as Senior Vice President, Commercial. Ms.
View HTML
Toggle Summary Liquidia Technologies Appoints Kevin Gordon as President and Chief Financial Officer View HTML
Toggle Summary Liquidia Technologies Files Registration Statement for Proposed Initial Public Offering of Common Stock
Liquidia Technologies, Inc. , a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT® technology to transform the lives of patients, today announced that it has filed a registration statement on Form S-1
View HTML
Toggle Summary Liquidia Technologies Provides Leadership Update
RESEARCH TRIANGLE PARK, N.C. , Nov. 27, 2018 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”) , a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT® technology to transform the
View HTML